AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Thrombin inhibitor used in coronary intervention lowers costs, study shows.
2004 DEC 2 - (NewsRx.com & NewsRx.net) -- The Medicines Company (MDCO) reported on a publication demonstrating significant in-hospital cost savings of $405 per patient (p
The REPLACE-2 clinical trial economic study was authored by David J. Cohen, MD, Harvard Clinical Research Institute, et al., and published in the November issue of the Journal of the American College of Cardiology (Vol. 44, Nov. 9, 2004).
The study was accompanied by an editorial comment paper by David F. Kong, MD, and Daniel B. Mark, MD (Duke Clinical Research Institute), who noted, "Bivalirudin appears to provide health benefits similar to existing therapies but for less money, a "win" for all parties. Economists refer to a therapy that fulfills these conditions as "dominant" and would expect its wide adoption into general practice."
The economic study was pre-specified in the protocol of the REPLACE-2 clinical trial, one of the largest studies of acute anticoagulation therapies (known as antithrombotics) ever conducted in patients undergoing percutaneous intervention.
REPLACE-2 was a randomized, double-blind comparison of Angiomax with provisional use of platelet glycoprotein 2b/3a inhibitors versus heparin plus platelet glycoprotein 2b/3a inhibitors.
The economic analysis was conducted prospectively by collecting hospital bills of the U.S. patients during REPLACE-2 enrollment. Cohen reported that the statistically significant cost advantages for ...
- The Medicines Company's Angiomax-R- -Bivalirudin- Saves Hospital Costs, Says...
- Press release article from: Business Wire November 2, 2004 700+ words
...than 0.001) with the use of Angiomax(R) (bivalirudin) in percutaneous...Cohen, MD (Harvard Clinical Research Institute) et al. and published in the...double-blind comparison of Angiomax with provisional use of platelet...
- Investigational Anticoagulant ANGIOMAX(TM) (formerly Hirulog(R) (bivalirudin))...
- Press release article from: PR Newswire October 28, 1999 700+ words
...Duke Clinical Research Institute, comes in conjunction...clinical trial of ANGIOMAX for study in HIT...Duke Clinical Research Institute allows HIT or...intervention to have ANGIOMAX available prior...worldwide rights to ANGIOMAX (formerly Hirulog...Duke Clinical ...
- REPLACE-2 Clinical Trial Economic Analysis Meets All Endpoints Demonstrating...
- Press release article from: Business Wire March 31, 2003 700+ words
...Day Follow-up Angiomax an Economically Dominant...the Harvard Clinical Research Institute presented the pre...Nasdaq:MDCO) Angiomax(R) (bivalirudin...of patients given Angiomax, were found to be...Harvard Clinical Research Institute) Variable Cost...
- Angiomax(R) (Bivalirudin) Recommended for Use in Percutaneous Coronary...
- Press release article from: Business Wire November 15, 2005 700+ words
...recommending that the direct thrombin inhibitor Angiomax(R) (bivalirudin) be used in patients...percutaneous coronary interventions (PCI). Angiomax is granted a Class IIa recommendation...STEMI). "We believe that inclusion of Angiomax in the guidelines will further accelerate...
- Angiomax(R) (bivalirudin) Monotherapy Superior to Heparins Plus GP IIb/IIIa...
- Press release article from: Business Wire March 12, 2006 700+ words
...Medicines Company's (Nasdaq: MDCO) Angiomax(R) (bivalirudin). The trial met its objectives in favor of Angiomax. The results were presented as a late...cut and even more robust in favor of Angiomax than the findings of our most recent...
- Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in...
- Press release article from: Business Wire October 24, 2007 700+ words
In Major Global Trial, Angiomax Reduced Net Adverse Clinical Events...angioplasty, the anti-clotting agent Angiomax([R]) (bivalirudin) resulted...Cardiovascular Research Foundation. Angiomax is available in Europe as Angiox...
- FDA Approves Expansion of Angiomax(R) (Bivalirudin) Label to Include Patients...
- Press release article from: Business Wire December 1, 2005 700+ words
...Administration (FDA) approved the use of Angiomax(R) (bivalirudin) in patients with...demonstrating that replacing heparin with Angiomax leads to better outcomes, particularly...Chief Operating Officer. "The updated Angiomax label will allow for broader dissemination...
- The Medicines Company Submits Angiomax -Bivalirudin- Supplemental NDA With U.S....
- Press release article from: Business Wire August 4, 2003 700+ words
...Administration (FDA) seeking an amended Angiomax(R) (bivalirudin) product label in...percutaneous coronary intervention (PCI). Angiomax was approved in the U.S. in December...life-threatening blood clots. "Angiomax has been evaluated in clinical studies...
Source: HighBeam Research, Thrombin inhibitor used in coronary intervention lowers costs, study...